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Abstract
Background: Cerebral malaria (CM) represents a severe outcome of the Plasmodium falciparum infection. Recent genetic
studies have correlated human genes with severe malaria susceptibility, but there is little data on genetic variants that
increase the risk of developing specific malaria clinical complications. Nevertheless, susceptibility to experimental CM in the
mouse has been linked to host genes including Transforming Growth Factor Beta 2 (TGFB2) and Heme oxygenase-1 (HMOX1).
Here, we tested whether those genes were governing the risk of progressing to CM in patients with severe malaria
syndromes.
Methodology/Principal Findings: We report that the clinical outcome of P. falciparum infection in a cohort of Angolan
children (n = 430) correlated with nine TGFB2 SNPs that modify the risk of progression to CM as compared to other severe
forms of malaria. This genetic effect was explained by two haplotypes harboring the CM-associated SNPs (Pcorrec. = 0.035
and 0.036). In addition, one HMOX1 haplotype composed of five CM-associated SNPs increased the risk of developing the
CM syndrome (Pcorrec. = 0.002) and was under-transmitted to children with uncomplicated malaria (P = 0.036). Notably, the
HMOX1-associated haplotype conferred increased HMOX1 mRNA expression in peripheral blood cells of CM patients
(P = 0.012).
Conclusions/Significance: These results represent the first report on CM genetic risk factors in Angolan children and
suggest the novel hypothesis that genetic variants of the TGFB2 and HMOX1 genes may contribute to confer a specific risk
of developing the CM syndrome in patients with severe P. falciparum malaria. This work may provide motivation for future
studies aiming to replicate our findings in larger populations and to confirm a role for these genes in determining the
clinical course of malaria.
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Introduction
Cerebral malaria (CM) is an acute life threatening complica-
tion of clinical malaria that afflicts a fraction of the P. falciparum-
infected patients and it is perceived as a complex syndrome,
rather than an isolated entity [1,2,3]. While potentially reversible,
CM can develop into an unfettered neurovascular inflammatory
syndrome leading to irreversible coma [3,4]. Studies on malaria
heritability indicate that about 25% of the risk to progress to
severe malaria is determined by human genetic factors [5,6]. The
strong protection against severe malaria conferred by the HbS [7],
G6PD [8,9,10] and the alpha-thalassemia mutations [11,12,13]
illustrate the striking selection pressure of malaria on the human
genome.
Genetic variation may in part determine the epidemiological
patterns of susceptibility/resistance to malaria observed at the
population level, whereby a fraction of the individuals infected
with the malaria parasite would present parasitaemia and
uncomplicated disease, a fraction of uncomplicated disease cases
would progress to severe disease and a fraction of severe disease
cases would develop CM syndrome [14]. Presumably, the genetic
factors controlling malaria severity would affect the risk of disease
progression from uncomplicated malaria, characterized by low
levels of parasitaemia and fever, towards the different severe
clinical complications and outcomes. Although many studies
emphasize the role of genetic factors in controlling the severity
of the malaria infection, in most instances the study design does
not allow comparisons of CM with non-cerebral forms of severe
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malaria [15,16,17,18] precluding the identification of genetic
variants that specify the risk of developing CM.
We performed a genetic study to test the prior hypothesis that
host factors influence specifically the risk of developing CM
syndrome in the context of severe malaria. The study design aimed
to identify candidate genetic variants associated to CM by
comparing a group of CM patients with a group of severe malaria
patients that did not exhibit CM. This hospital-based study was
carried out in Luanda, a province of Angola that represents a
mesoendemic stable region and where malaria is the first cause of
morbidity and mortality [19]. Malaria transmission in Angola is
perennial with enhancement during the rainy season and P.
falciparum malaria is the most frequent infection (Angolan Ministry
of Health, MINSA 2001).
The study of CM pathogenesis has benefited from investigations
on experimental systems that use artificial laboratory infections to
develop rodent models of experimental cerebral malaria (ECM).
This report focused on four functional candidate genes (TGFB2,
HMOX1, ICAM1 and CD36) that have been correlated with CM
and other forms of severe malaria in mouse models. To our
knowledge the TGFB2 gene has not been studied in the context of
human malaria but it was suggested to confer resistance to ECM
in a wild mouse strain. Heme oxygenase -1, encoded by Hmox1
gene, was shown to prevent the development of ECM but its role
in human CM has not been addressed other than by an
exploratory study in CM patients in Myanmar [20]. The ICAM
1 and CD36 genes have also been related to ECM in the mouse
models [21,22] but investigations on the role of these genes in
human CM and severe malaria led to inconclusive and often
contradictory results [15,23,24,25,26,27,28,29].
This work represents an initial report on CM genetics in the
Angolan population and though requiring further confirmation in
larger samples from other populations, the results suggest that
TGFB2 gene variants contribute to the risk of developing the CM
syndrome when compared to other forms of severe malaria in
Angolan children. The results also suggest that HMOX1 gene
variants are associated to CM risk and control the HMOX1 mRNA
expression in peripheral blood cells of children with CM.
Results
The sample population in this study consisted of 430 children
diagnosed with malaria in the central pediatric hospital of Luanda
(Angola) and the 319 uninfected apparently healthy controls, all
attendees to the vaccination ward of the same hospital. A fraction
of the CM patients (16.9%) showed severe malaria anemia and
11.5% also had hyperparasitaemia. Nevertheless, we did not find
association between hyperparasitaemia and severe anemia (Chi-
Square test, P value = 0.58) and 47.7% of the CM patients had low
parasitaemia levels, suggesting that high levels of parasitaemia
were not a requirement to develop CM. The ethnic group
Kimbundu that predominates in Luanda was the most represented
in our study (50.7%), while Umbundu was the second ethnic group
(13.7%). Nevertheless, the ethnic composition did not differ among
patient groups (Kruskal-Wallis Test, P-Value = 0.56) and there was
no association between ethnic groups and malaria outcome (Chi-
Square test, P-value = 0.74) suggesting that ethnic ancestry was not
a major factor in stratifying the clinical malaria phenotypes.
All individuals were genotyped and analyzed for 54 single
nucleotide polymorphisms (SNPs) that covered a region of 100Kb
that encompassing the TGFB2 gene (Transforming growth factor, beta
2), 3.1 Kb in the CD36 gene (Thrombospondin receptor), 3.3 Kb in the
HMOX1 (Heme oxygenase -1) gene region, 5.2 Kb in the ICAM 1
(Intercellular adhesion molecule 1, CD54) gene region as well as dbSNP
rs334 which defines the HbS mutation. The complete list of SNPs
that passed genotyping quality control and were subjected to
association analysis is shown in Table S1. For the analyzed SNPs
the Hardy-Weinberg (HWE) was preserved in all patient groups
and uninfected apparently healthy controls, except for the HbS
mutation that was in equilibrium in the healthy controls but not in
the malaria patient groups.
To identify genetic polymorphisms specifically associated to
CM, we used the strategy of comparing genotype frequencies
between 130 patients with the CM syndrome and 158 patients
with severe forms of malaria severe malaria in absence of CM
(SnC). To better define CM-associated genetic factors that are
exclusively detected when comparing CM to SnC patients, the
study included a group of 142 patients with uncomplicated malaria
(UM) and 319 uninfected healthy controls (UIF). The evaluation
of the genetic association tests took into account that the sample
size limited the resilience to multiple test corrections. Therefore,
the initial single marker analysis was used to identify SNPs with
suggestive effects on the CM phenotype and the subsequent
analysis was pursued in the context of haplotype association using
corrected P values (see methods section).
Single marker analysis
Genotype frequency analysis showed the frequency of the HbS
mutation (rs334) did not differ significantly between CM and SnC
patients but was notably higher in UM patients and UIF controls
(Table 1). These results confirmed that the well-documented
protective effect of the HbS mutation against severe malaria [7,30]
is measurable in the Angolan population and suggested that the
sickle cell anemia trait is not specifically protecting from CM
development.
To identify genetic polymorphisms that specifically modify the
risk of developing CM, we searched for genotype differences
between patients having CM and those having severe malaria in
absence of CM (SnC). We found that the genotype frequencies in
9 out of the 26 SNPs analyzed in the TGFB2 gene and 3 out of 10
SNPs analyzed in HMOX1 gene showed suggestive association to
CM (uncorrected P-value,0.05) when comparing CM patients
with SnC patients but not in comparison with UM patients and
UIF controls (Table 1). These results raised the possibility that
variants of these genes could be involved in specifying the risk of
developing CM in the context of severe malaria. Also, we noted
that an additional SNP in the HMOX1 gene (rs2071748) showed
significant association only when comparing CM with UM
patients (Table 1). This finding suggested that the SNP
rs2071748 could represent a risk factor for severe malaria, which
was also detected when comparing SnC to UM patients (data not
shown). This SNP maps very closely to the GT repeat
polymorphism that has been associated to CM in a study in the
Myanmar population [41]. We genotyped this microsatellite and
found that the frequency of the GT-repeat short alleles tends to be
higher in CM patients as compared to UIF controls (P = 0.0057)
and to UM patients (P = 0.038) but not when compared to SnC
patients (see Figure S1 and Table S2). This result suggests that the
rs2071748 CM-association signal was also captured by the
HMOX1-GT repeat. In contrast, two SNPs on the CD36 gene
which was previously reported to be associated with disease
severity [28,31,32], showed to be associated to CM when
comparing to SnC patients but also with UM patients and UIF
controls (Table 1). This result suggested that genetic variants of the
CD36 gene play a role at various stages of disease progression but
are not specifically involved in specifying the clinical outcome of
the severe malaria. We also found that the SNPs of the ICAM 1
gene were not associated to CM (Table S3).
Genetics of Cerebral Malaria
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Linkage Disequilibrium analysis
We used linkage disequilibrium (LD) analysis to take into account
the relative positions of the CM-associated SNPs in the TGFB2 and
HMOX1 genes. Out of the 26 SNPs that were analyzed across
100 kb in the TGFB2 region, the nine SNPs specifically associated
with CM clustered in a region spanning 48 Kb. LD analysis
revealed a region of strong LD covering 27 kb of the structural
TGFB2 gene that encompassed eight SNPs associated with CM.
The remaining CM-associated SNP (rs1317681) maps 15 kb from
this region and showed a weaker statistical association to CM
(Table 1). The r2 among the eight SNPs varied from 0.6 to 1.0
suggesting that this region may represent a LD block in the TGFB2
gene (Figure 1). Similarly, we found that 5 out the 10 SNPs analyzed
in the HMOX1 gene were mapping within a strong LD group
(r2.0.9) that spanned approximately 8 kb. This region encom-
passed the three SNPs associated with CM, one SNP (rs9622194)
marginally associated with CM (P-value = 0.06) (Table S3) and the
SNP (rs2071748) associated with disease severity (Figure 2).
Haplotype association
The results of the LD analysis were used to reconstruct
haplotypes (R package GAP) of the TGFB2 and HMOX1 genes
and test whether the most frequent haplotypes (.5%) were
associated to CM correcting statistical significance using permu-
tation tests. Using the eight SNPs that showed exclusive CM-
specific association within the TGFB2 LD block we reconstructed
six haplotypes that were denoted TGFB2a to TGFB2e (Table 2).
The analysis confirmed the overall association (Global Score
Statistics) of the TGFB2 haplotypes when comparing CM with
SnC patients (corrected P-value = 0.041). TGFB2c and TGFB2f
haplotypes with distinct alleles in all seven CM-associated SNPs,
showed opposite effects on the risk of developing CM (Table 2).
The TGFB2c was significantly more frequent in CM patients than
in those with other forms of severe malaria (corrected P-
value = 0.035) and its genetic effect appears to be restricted to
increase the risk of developing CM in the context of severe
malaria. In contrast, the TGFB2f haplotype that was less frequent
Table 1. Association results for cerebral malaria risk single-nucleotide polymorphisms (SNPs) genotyped in TGFB2, CD36, HBB and
HMOX1 genes.
GENE dbSNP (RA) RA frequency (%) P Odds Ratio (CI)
CM
(2n = 260)
SnC
(2n = 316)
UM
(2n = 284)
UIF
(2n = 638) CM/SnC CM/UM CM/UIF
TGFB2 rs1317681
(T)
17.5 12.3 13.1 15.3 0.047
1.72 (1.00–2.96)
1.52 (0.88–2.60) 1.27 (0.81–1.99)
rs1934852
(A)
56.6 46.7 51.8 50.6 0.034
1.79 (1.04–3.12)
1.43 (0.83–2.44) 1.32 (0.83–2.08)
rs6657275
(G)
56.2 47 51.4 50.2 0.04
1.75 (1.02–2.94)
1.43 (0.85–2.44) 1.35 (0.86–2.08)
rs1342586
(T)
18.9 11.1 15.7 14.7 0.015
1.95 (1.14–3.34)
1.28 (0.76–2.15) 1.31 (0.84–2.04)
rs4846478
(G)
43.4 34.6 39.1 38.6 0.034
1.70 (1.04–2.79)
1.29 (0.78–2.15) 1.38 (0.89–2.14)
rs6684205
(G)
56.0 47.0 51.4 50.0 0.046
1.72 (1.01–2.94)
1.43 (0.83–2.44) 1.33 (0.85–2.08)
rs1418553
(C)
56.0 46.7 51.4 50.0 0.041
1.75 (1.02–3.03)
1.43 (0.83–2.43) 1.33 (0.85–2.08)
rs900
(T)
43.0 34.3 38.7 39.1 0.03
1.70 (1.04–2.77)
1.30 (0.79–2.15) 1.32 (0.85–2.03)
rs1473527
(A)
71.0 64.9 69.1 66.9 0.03
1.69 (1.05–2.78)
1.02 (0.63–1.64) 1.37 (0.90–2.08)
CD36 rs1194182
(G)
40.2 29.9 32.3 31.4 0.016
1.51 (1.08–2.12)
1.37 (0.97–1.92) 0.003
2.65 (1.46–4.80)
rs3211821
(G)
41.5 31.9 29.9 33.7 0.024
1.48 (1.05–2.08)
0.006
1.64 (1.14–2.34)
0.033
1.39 (1.03–1.87)
rs1358337
(C)
46.3 41.1 36.8 39.9 1.22 (0.88–1.70) 0.038
1.42 (1.02–1.98)
0.025
1.82 (1.09–3.05)
HBB rs334
(T)
2.7 4.6 11.0 15.1 0.58 (0.19–1.73) 0.0009
0.22 (0.08–0.60)
0.161029
0.11 (0.04–0.28)
HMOX1 rs2071748
(A)
70.9 71.8 62.8 65.3 1.05 (0.72–1.53) 0.043
1.47 (1.01–2.12)
1.28 (0.93–1.75)
rs8139532
(G)
55.2 48.3 52.5 53.0 0.025
1.85 (1.07–3.22)
1.35 (0.8–2.33) 1.27 (0.81–2.0)
rs7285877
(C)
55.3 48.0 53.6 53.4 0.024
1.85 (1.07–3.22)
1.25 (0.74–2.13) 1.27 (0.80–2.0)
rs11912889
(G)
54.4 47.3 50.7 52.8 0.032
1.81 (1.05–3.22)
1.30 (0.76–2.22) 1.31 (0.83–2.08)
Abbreviations: CM, cerebral malaria; SnC, severe no cerebral malaria; UM, uncomplicated malaria; UIF, uninfected; RA, reference allele. P-values and Odds Ratios were
obtained by logistic regression analysis. Allele frequencies refer to the reference allele conferring susceptibility or resistance to CM.
doi:10.1371/journal.pone.0011141.t001
Genetics of Cerebral Malaria
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11141
in the population significantly decreased the risk of progression to
CM (corrected P value = 0.036). This protective effect is inferred
from the reduction of the TGFB2f haplotype frequency among the
CM patients that is still detectable when comparing CM patients
to UIF controls (Table 2).
Haplotype reconstruction using the five SNPs in the LD block of
the HOMX1 gene identified three haplotypes denoted HMOX1a,
HMOX1b and HMOX1c (Table 3). Association analysis revealed
that the HMOX1c haplotype frequency was significantly higher in
CM patients as compared to SnC and UM patients as well as to
uninfected controls (Table 3). These results suggest that the
HMOX1c haplotype has a general role as a CM syndrome
susceptibility factor particularly when compared to uncomplicated
malaria patients (P = 0.002). On the other hand, the HMOX1b
haplotype showed a CM protective effect with marginal
significance when comparing CM with UM patients (corrected
P-value = 0.056). In fact, the frequency of the HMOX1b
haplotype was similar in CM patients and in patients with severe
non-cerebral malaria. This finding suggested that this haplotype
act at different stages of infection as a factor conferring protection
from severe malaria (Table 3).
Transmission disequilibrium tests
We used transmission disequilibrium tests (TDT) in mother-
affected child pairs to corroborate the haplotype associations
observed in the case-control analysis. The TDT analysis was
performed with the TRANSMIT software using 105 mother-
affected child pairs with CM, 115 with SnC and 106 with UM.
Figure 1. Association tests and LD analysis in the TGFB2 gene single-nucleotide polymorphisms (SNPs). The diagram represents in the
vertical axis, the log10 of the P value of association tests of SNPs listed in the y-axis, obtained from logistic regression analysis. The points in red, blue
and green represent the results of the association with the SNPs between cases of cerebral malaria (CM) and controls with severe no cerebral malaria
(SnC), uncomplicated malaria (UM) and uninfected (UIF), respectively. The upper diagram shows a scale representation of the structure of the TGFB2
gene: exons are represented by boxes and marked with its number. The bottom of the diagram represents the LD between a pair of SNPs measured
by r2. The image, below and to the left, corresponds to the color scale representing the values of LD, from yellow (r2 = 0) to red (r2 = 1). This diagram is
an adaptation of the figure produced by the snp. plotter R package.
doi:10.1371/journal.pone.0011141.g001
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The TDT analysis detected the protective role of the HbS
mutation as it was under-transmitted to CM children (P = 0.036)
(Table 4). Moreover, we found that the TGFB2c haplotype
(AGATGGTTA), deemed to be overrepresented in severe malaria
patients that progressed to CM, was under-transmitted to SnC
children that did not progress to cerebral malaria (P = 0.038)
(Table 4). On the other hand, the HMOX1c haplotype (AGCGG)
was found to be under-transmitted to UM children (P = 0.036),
reinforcing the hypothesis that this haplotype represents a risk
factor for severe malaria (Table 4). Overall, the TDT results
corroborated the initial case-control association findings for
haplotypes that showed relatively high frequency. Failure to
confirm associations of less frequent haplotypes (e.g. TFB2f) by
TDT is presumably due to reduced statistical power. Nevertheless,
the results of the TDT analysis suggested that the associations of
TGFB2 and HMOX1 genes to CM are not attributable to
population stratification effects in groups of patients and controls.
HMOX1 SNPs control HMOX1 mRNA expression in
children developing CM
To investigate the functional basis of HMOX1 association to
malaria we examined whether the HMOX1 haplotypes associated
to the clinical outcomes of malaria were also controlling the level
of HMOX1 gene expression among children developing CM.
Relative expression of HMOX1 mRNA in 42 children developing
CM was quantified by Real-Time PCR in peripheral blood
leukocytes. The basal levels were fairly high, as judged from the
Figure 2. Association tests and LD analysis in the HMOX1 gene single-nucleotide polymorphisms (SNPs). The diagram represents in the
vertical axis, the log10 of the P value of association tests of SNPs listed in the y-axis, obtained from logistic regression analysis. The points in red, blue
and green represent the results of the association with the SNPs between cases of cerebral malaria (CM) and controls with severe no cerebral malaria
(SnC), uncomplicated malaria (UM) and uninfected (UIF), respectively. The upper diagram shows a scale representation of the structure of the HMOX1
gene: exons are represented by boxes and marked with its number. The bottom of the diagram represents the LD between a pair of SNPs measured
by r2. The image, below and to the left, corresponds to the color scale representing the values of LD, from yellow (r2 = 0) to red (r2 = 1). This diagram is
an adaptation of the figure produced by the snp. plotter R package.
doi:10.1371/journal.pone.0011141.g002
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Real-Time PCR CTs with prominent curves. Quantitative trait
locus (QTL) analysis detected suggestive association of the
HMOX1c haplotype (AGCGG) to the level of HMOX1 mRNA
expression (P#0.01) (Table 5). This result revealed that the
HMOX1c genetic variant that conferred increased risk to develop
CM is also associated to higher expression of HMOX1 mRNA in
the context of CM.
Discussion
In this work, we aimed to identify genetic variants specifying the
emergence of CM in severe malaria patients by contrasting
genotype frequencies in those patients presenting CM with those
exhibiting signs of severe malaria but exempt of CM symptoms.
Single marker analysis suggested that SNPs in the TGFB2 and
HMOX1 genes showed specific association to the CM syndrome.
In addition, haplotype association analysis showed that the
TGFB2c haplotype specifically increased the risk of developing
CM as compared to other severe malaria complications. This
haplotype was also under-transmitted to patients with severe non-
cerebral malaria. On the other hand, the HMOX1c haplotype
seemed to play a general role in CM risk as it was overrepresented
in CM patients as compared to SnC and UM patients as well as to
uninfected controls. In accordance, this haplotype was under-
transmitted to patients with uncomplicated malaria. Moreover,
QTL analysis showed that the HMOX1c haplotype was associated
to higher expression of HMOX1 mRNA in peripheral blood cells
of CM patients.
We did not find that CD36 was a determinant of the risk of
developing CM as compared to other severe malaria complica-
tions. In fact, the role of the CD36 gene in malaria is still debated
and raises the question of whether different studies may capture
different effects of the CD36 gene variants in severe and in cerebral
malaria. We found that the SNP rs3211958 was not associated to
CM although this SNP is known to be in complete LD with
rs3211938 which showed contradictory results in different African
populations [15,26,28,33]. In our sample, the absence of CM-
association with the ICAM 1 SNPs is in agreement with the results
reported by a study in Gambia, Malawi and Kenya populations
[26], though it has been reported that the heme oxygenase-1 has a
down-regulating effect on the ICAM-1 expression levels [34,35].
Such heterogeneity effects should be kept in mind when judging
lack of replication of many reported SNP associations to disparate
malaria clinical manifestations [36,37,38].
Table 2. Association results for TGFB2 haplotypes.
Haplotypes Haplotype frequencies (%) Cerebral Malaria versus Controls P (Hap-Score)
CM
(2n = 260)
SnC
(2n = 316)
UM
(2n = 284)
UIF
(2n = 638) CM/SnCa CM/UMb CM/UIFc
TGFB2a
CAGCCACAG
29.0 35.8 32.5 32.9 0.83
(21.68)
0.40
(20.79)
0.28
(21.07)
TGFB2b
AGACGGTTA
24.0 23.0 23.5 23.6 0.80
(0.27)
0.90
(0.11)
0.93
(0.06)
TGFB2c
AGATGGTTA
18.3 11.5 16.0 14.8 0.035
(2.21)
0.33
(0.96)
0.20
(1.36)
TGFB2d
AGATCGTAA
13.7 12.5 11.2 11.7 0.70
(0.41)
0.60
(0.69)
0.57
(0.65)
TGFB2e
CAGCCACAA
9.8 7.6 7.5 8.5 0.36
(0.89)
0.34
(0.86)
0.47
(0.83)
TGFB2f
CAACCACAA
4.7 9.7 9.3 8.3 0.036
(22.26)
0.037
(22.08)
0.049
(21.92)
Abbreviations: CM, cerebral malaria; SnC, severe no cerebral malaria; UM, uncomplicated malaria; UIF, uninfected. Hap-Score represents susceptibility (positive values) or
resistance (negative values). In each haplotype are sequentially represented the alleles from SNPs of the LD block: rs1934852, rs6657275, rs6671370, rs1342586,
rs4846478, rs6684205, rs1418553, rs900 and rs1473527. Haplotypes represented have frequency.5% in UIF. Global Score Statistics Corrected P: a) 0.041; b) 0.26; c) 0.41.
doi:10.1371/journal.pone.0011141.t002
Table 3. Association results for HMOX1 haplotypes.
Haplotypes Haplotype frequencies (%) Cerebral Malaria versus Controls P (Hap-Score)
CM
(2n = 260)
SnC
(2n = 316)
UM
(2n = 284)
UIF
(2n = 638) CM/SnCa CM/UMb CM/UIFc
HMOX1a
AATAA
41.3 45.7 42.1 43.2 0.37
(20.90)
0.94
(20.04)
0.61
(20.50)
HMOX1b
GGCGG
29.1 28.0 37.5 34.7 0.70
(0.36)
0.06
(21.94)
0.22
(21.26)
HMOX1c
AGCGG
22.7 14.8 11.7 14.6 0.03
(2.12)
0.002
(3.06)
0.01
(2.41)
Abbreviations: CM, cerebral malaria; SnC, severe no cerebral malaria; UM, uncomplicated malaria; UIF, uninfected. Hap-Score represents susceptibility (positive values) or
resistance (negative values). In each haplotype are sequentially represented the alleles from SNPs of the LD block: rs2071748, rs8139532, rs7285877, rs11912889 and
rs9622194. a) Global Score Statistics Corrected P = 0.06; b) P = 0.009; c) P = 0.10.
doi:10.1371/journal.pone.0011141.t003
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Though the pathogenesis and the symptoms of cerebral malaria
in murine CM do not completely overlap the observations in
human CM, the mouse models have brought critical insights to
our understanding of CM pathogenesis [39,40,41]. Thus the
TGFB2 gene was identified as a candidate gene to CM
susceptibility in a genetic cross that used wild-derived mouse
strains and where CM susceptibility segregated from hyperpar-
asitaemia [42], suggesting that TGFB2 would be a gene conferring
risk to CM in the context of severe malaria. Tgfb22/2 mice are
not viable and studies with heterozygous mice in the context of
malaria infection are warranted and may provide further evidence
of involvement of the Tgfb2 gene in ECM pathogenesis.
Members of the TGF-beta cytokine family have been associated
to the control of malaria infection and parasite growth [43,44,45]
and TGFB isoforms were shown to accumulate in the brain of
cerebral malaria patients [46]. The study of the TGFB2 haplotypic
structure in the Angolan population led us to identify an LD block
covering 27kb in the structural region of the gene. Although the
CM-associated region in the TGFB2 gene covers part of the coding
region, all the SNPs that we analyzed were intronic and have no
predicted effects in folding, activity or function of the TGFB2
protein. Re-sequencing of relevant variants of the TGFB2 gene
may provide further information on putative functional polymor-
phisms explanatory of the role of TGFB2 in CM pathogenesis.
Studies of TGFB2 haplotypes in other populations and areas with
different malaria endemicity would be required to determine
whether the TGFB2 genetic variance represents a widespread CM
risk factor. It should be noted that according to our observations
the replication of TGFB2 specific association to CM in other
populations is expected to be stronger when analyzed in the
context of severe malaria.
The Heme oxygenase-1 activity has been shown to suppress
ECM in mice [47] and one report in Myanmarese patients
suggested that short alleles of a GT repeat in the HMOX1
promotor region are a risk factor for cerebral malaria [20]. Here,
we show that one haplotype (HMOX1c) composed by SNPs
covering a 8Kb LD block in the structural region of the HMOX1
gene confers susceptibility to CM which (Table 3). Strikingly, the
occurrence of the allele A at position rs2071748 in the context of
this haplotype generates the HMOX1b haplotype that marginally
decreases the risk to progress from UM to CM. It is worth noting
that the A at position rs2071748 is not able to mediate CM
susceptibility in the context of the high frequency HMOX1a
haplotype (Table 3). We also noted that the rs2071748 SNP was
mapping in the HMOX1 promotor region very closely to the GT
repeat polymorphism that showed that the short alleles were
overrepresented in our CM patients and in Myanmar patients
[20]. We also found that the HMOX1c haplotype governs the
expression of HMOX1 mRNA in peripheral blood leucocytes
(PBL) of CM patients. We speculate that HMOX1 gene expression
measured in PBLs could reflect the ability of blood cells to express
this gene in the brain. Thus, our results raise the possibility that
HMOX1 variants may control the risk of CM through regulation of
HMOX1 expression. Nevertheless, we cannot exclude that relative
differences in PBLs lineages among CM patients could influence
HMOX1 gene expression measurements. Overall, the HMOX1
association analysis suggests that the involvement of this gene in
determining the outcome of malaria infection might be related to
disease severity and not exclusively to the CM syndrome.
Our results highlight the value of a study design centered in a
particular clinical manifestation of malaria, namely CM, and
comparing that clinical manifestation with other frequent
outcomes, including non-cerebral forms of malaria (SnC group)
or uncomplicated malaria (UM group). This enabled the
identification of genetic variants associated with CM in the
context of severe malaria syndromes. Thus, the clinical stratifica-
tion approach we used in this study could prove a useful tool to
complement genome-wide association analysis of malaria [48,49]
allowing fine-resolution association analysis of candidate genes and
taking into account the haplotypic context and the genetic
variability within African populations [50,51].
This work represents an initial study on genetics of CM in the
Angolan population. The statistical evidence supporting the
described genetic association findings was limited by the relatively
small sample size, by the genetic heterogeneity of the Angolan
population, by the presumed small genetic effects and by lack of
knowledge of yet to describe causal genetic variants possibly
located within the CM associated regions. Although these factors
limit the extrapolation of the association results to other
populations our findings suggest the novel hypothesis that in
African populations the TGFB2 and HMOX1 genetic variation
correlate with malaria genetic susceptibility.
Table 4. Transmission disequilibrium tests for associated
TGFB2 and HMOX1 haplotypes and dbSNP rs334.
Haplotype/
dbSNP Phenotype Observ. Expec. Var (O-E) P
TGFB2c
AGATGGTTA
CM 20.0 18.9 5.3 0.65
SnC 7.3 11.1 3.2 0.038
UM 13.9 12.6 3.9 0.53
TGFB2f
CAACCACAA
CM 8.0 7.9 2.6 0.92
SnC 5.7 5.1 1.7 *
UM 5.0 3.7 1.1 *
HMOX1b
GGCGG
CM 56.3 59.4 15.2 0.49
SnC 67.8 69.1 14.7 0.72
UM 75.9 71.5 14.7 0.30
HMOX1c
AGCGG
CM 42.2 39.8 10.8 0.54
SnC 34.2 37.0 10.5 0.42
UM 23.1 32.5 9.0 0.0036
rs334 CM 7.0 11.4 3.8 0.036
*Low frequency in the mother-descendent pairs precluded the analysis.
Abbreviations: CM, cerebral malaria; SnC, severe no cerebral; Var (O-E), variance
(observed-expected).
doi:10.1371/journal.pone.0011141.t004
Table 5. Haplotypic quantitative trait analysis of HMOX1 gene
expression in cerebral malaria patients.
Haplotype BETA STAT P
HMOX1a
AATAA
21.88 3.82 0.06
HMOX1b
GGCGG
0.36 0.12 0.74
HMOX1c
AGCGG
3.18 8.70 0.012
Beta, genetic effect under logistic regression model; Stat, test statistic; P,
empirical p-value.
doi:10.1371/journal.pone.0011141.t005
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This report may provide insights and motivation for future
association and functional studies aiming to replicate our findings
in larger populations and to confirm a role for TGFB2 and
HMOX1 in determining the course of disease in the response to
Plasmodium infections.
Materials and Methods
Subjects, Phenotypic and Clinical Criteria
A total of 749 children, living in Luanda and ranging from 6
months to 13 years of age were enrolled in the present study.
Ethical permission for this study was granted by the Ethical
Committee of the Hospital Pedia´trico David Bernardino (HPDB)
in Luanda that was appointed by the Angolan Ministry of Health.
Written, informed consent was obtained from the parents or
guardians of each child. Patients were selected among attendance
to the HPDB. Uninfected controls were sampled from children
randomly selected in the vaccination ward of the HPDB. The
sample collection was carried out from February 2005 to May
2007 and comprised 130 CM children (cases), 158 patients with
severe malaria but not CM (SnC), 142 patients with uncompli-
cated malaria (UM) and 319 uninfected controls (UIF). The mean
age in months was 54.2 for CM cases, 45.9 for SnC patients, 50.3
for UM patients and 60.9 for UIF controls. Ethnicity was defined
on a parental basis and the major ethnic groups were the
Kimbundu and Umbundu. Malaria was diagnosed on the basis of
a positive asexual parasitaemia detected on a Giemsa-stained thick
smear. For parasitaemia quantification the number of parasites per
100 high-power microscopic fields was estimated and the parasite
density was calculated from this value [52]. CM was defined
according to the WHO criteria: a coma score,3 in Blantyre Scale
for children ,60 months or a coma score ,7 in Glasgow Scale for
children $60 months. Meningitis and encephalitis were ruled out
by cerebrospinal fluid analysis after lumbar puncture. Exclusion
criteria were a different known aetiology of encephalopathy and
hypoglycaemia (glycaemia ,40 mg/dl). A fraction of CM patients
showed as part of the CM syndrome additional clinical
complications such as severe malaria anaemia (SMA) and
hyperparasitaemia (HPM). The severe non-CM group (SnC)
included patients with SMA and/or HPM. Children with HPM
had $100 red blood cells parasitized by one high-power
microscopic field and SMA was defined by haemoglobin ,5 g/
dl or hematocrit ,15%. Patients with consciousness disturbances
or with other disease were excluded from this group. The
uncomplicated malaria (UM) group represents patients with
malaria diagnosis and febrile illness without any clinical finding
suggestive of other causes of infection and with no manifestations
of severe malaria. All the uncomplicated malaria patients were
outpatients. Patient treatments followed the established hospital
guidelines. Enrollment of uninfected controls excluded children
with any clinical finding suggestive of illness and the uninfected
status was confirmed by the absence of Plasmodium DNA in the
peripheral blood as detected by PCR [53].
Sample Preparation, Candidate Genes and Genotyped
SNPs
Genomic DNA was extracted from whole blood using the
Chemagen Magnetic Bead Technology. DNA preparations were
quantified using PicoGreen reagents according to the supplier
instructions.
All the 749 children and their mothers were genotyped and
analyzed for 54 SNPs in the following genes: TGFB2 (Transform-
ing growth factor, beta 2), HBB (b-globin), CD36 (Thrombospon-
din receptor), HMOX1 (Heme oxygenase 1) and ICAM 1 (Intercellular
adhesion molecule 1, CD54). A complete list of genotyped SNPs is
available in Table S1.
When selecting SNPs to genotype we prioritized those that were
previously associated with CM, preferentially confirmed by
sequencing and those belonging to distinct LD blocks as judged
from the HapMap database (http://www.hapmap.org). The SNP
genotyping method used the Mass Array system to design
multiplex reactions for PCR and iPlex primer extension
(Sequenom) and the MALDI-TOF based Mass Array genotype
platform (Sequenom). Genotyping quality control selected SNPs
that yield correct genotypes according HapMap control samples,
passed the Hardy-Weinberg equilibrium test (P.0.05) with a
calling rate .90%.
HMOX1 gene specific expression by qRT-PCR
For gene-specific expression, total RNA was obtained from
500 ml of whole blood from 42 CM patients collected to RNAlater
solution (to stabilize RNA) using the RiboPure-Blood Kit
(Ambion). One microgram of total RNA was converted to cDNA
(Transcriptor High Fidelity cDNA Synthesis Kit, Roche) and
HMOX1 expression was quantified using TaqMan Gene Expres-
sion Assay Hs00157965_m1 from ABI with TaqMan Gene
Expression master mix. The qRT-PCR was performed according
to the manufacturer instructions on an ABI Prism 7900HT system.
Relative quantification of HMOX1 specific mRNA was obtained
after normalization for HPRT1 mRNA expression measured in the
same PCR reaction.
Data analysis
Data analysis followed a step-wise strategy. Firstly, case-control
association analysis was performed for individual SNPs. Genotypic
association of SNPs with susceptibility to malaria was analyzed
using logistic regression models implemented in the SNPassoc
package [54] for the R statistical software (version 2.7.0). An
uncorrected significance level of the likelihood ratio test
(P-value ,0.05) was considered as suggestive evidence for
association. Secondly, linkage disequilibrium (LD) maps were
constructed exclusively for genes that demonstrated multiple SNPs
associated to CM only when comparing CM cases to SnC
controls. This analysis only pursued for genes that showed multiple
polymorphisms associated to CM, exclusively when comparing
CM patients to SnC patients. Pairwise LD was estimated using the
correlation coefficient (r2) and the LD map was visualized using
the snp.plotter R package [55] and was used to identify LD blocks
within gene regions. In a third step, we used the gene counting
method available in the R package GAP to reconstruct haplotypes
composed with multiple associated SNPs within an LD block [56].
We intended to determine whether particular genotypic combi-
nations of the CM-associated SNPs could confer a single joint
specific effect on the risk of developing CM. Association between
haplotypes and susceptibility to malaria was also evaluated with
logistic regression analysis, using the same package that calculates
global and haplotype-specific score statistics. Significant global
score statistics (GSS) indicate that haplotype-specific scores (hap-
score) are valid. A significant positive hap-score means that the
haplotype confers susceptibility to the trait and a negative hap-
score relates to protection [57]. For each haplotype, empirical P-
values were calculated by permutation tests using the Monte-Carlo
method to generate 1000 data simulations.
Finally, a family-based test using the TRANSMIT software [58]
was performed for HbS and for haplotypes significantly associated
to CM. Due to difficulties in collecting both parents, we took the
conservative option of restricting the analysis to mother-descen-
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dent pairs performing the TDT analysis in children and their
mothers.
Haplotypic quantitative trait association analysis for HMOX1
gene expression levels was analyzed by the logistic regression
model implemented in the Plink Package (version number 1.06)
which calculates P values using empirical significance (http://
pngu.mgh.harvard.edu/purcell/plink/) [59].
Supporting Information
Table S1 Genotyped single nucleotide polymorphisms.
Found at: doi:10.1371/journal.pone.0011141.s001 (0.08 MB
DOC)
Table S2 Allelic distribution of the HMOX1 GT repeat in
distinct patient groups and uninfected controls.
Found at: doi:10.1371/journal.pone.0011141.s002 (0.04 MB
DOC)
Table S3 Cerebral malaria association tests for single-nucleotide
polymorphisms (SNPs) in the HMOX1, CD36 and ICAM1 genes.
Found at: doi:10.1371/journal.pone.0011141.s003 (0.07 MB
DOC)
Figure S1 Relative frequency distribution of the HMOX1
repeat alleles in distinct malaria phenotypes.
Found at: doi:10.1371/journal.pone.0011141.s004 (0.06 MB
DOC)
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